Payment overview · 2025
General Payments
$746.82
33 reported records · 7 companies
Healthcare provider profile · identity verified
Robert W Powers, DO
Allopathic & Osteopathic Physicians|Internal Medicine · ROGERSVILLE, MO · NPI 1881699072
Verified facts
What the public records show
CMS Open Payments records show Robert W Powers, DO received $746.82 in general payments during 2025 across 33 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 34.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ingrezza, Ozempic, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $259.88 | 34.8% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $206.63 | 27.7% | 10 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $175.74 | 23.5% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.46 | 5.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.01 | 5.0% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.13 | 2.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.97 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $746.82 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $275.01 | 9 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $175.74 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $135.08 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $71.55 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $52.23 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.46 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $37.01 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 756 | 74 |
| Gabapentin | Gabapentin | 704 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 646 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 549 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 486 | 65 |
| Mirtazapine | Mirtazapine | 451 | 47 |
| Potassium Chloride | Potassium Chloride | 448 | 58 |
| Eliquis | Apixaban | 440 | 35 |
| Metformin Hcl | Metformin Hcl | 426 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 422 | 60 |
| Lisinopril | Lisinopril | 416 | 56 |
| Furosemide | Furosemide | 411 | 55 |
| Omeprazole | Omeprazole | 404 | 44 |
| Trazodone Hcl | Trazodone Hcl | 401 | 54 |
| Buspirone Hcl | Buspirone Hcl | 386 | 41 |
| Sertraline Hcl | Sertraline Hcl | 381 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 372 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 323 | 42 |
| Famotidine | Famotidine | 280 | 39 |
| Donepezil Hcl | Donepezil Hcl | 272 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 268 | 44 |
| Carvedilol | Carvedilol | 265 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 263 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 244 | 31 |
| Xarelto | Rivaroxaban | 243 | 18 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 222 | 34 |
| Losartan Potassium | Losartan Potassium | 217 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 215 | 23 |
| Alprazolam | Alprazolam | 207 | 34 |
| Lorazepam | Lorazepam | 207 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 205 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 198 | 29 |
| Allopurinol | Allopurinol | 186 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 178 | 26 |
| Memantine Hcl | Memantine Hcl | 177 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 173 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 171 | 19 |
| Myrbetriq | Mirabegron | 170 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 30 |
| Baclofen | Baclofen | 138 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 135 | 17 |
| Prednisone | Prednisone | 130 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 129 | 17 |
| Tramadol Hcl | Tramadol Hcl | 128 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 126 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 27 |
| Spironolactone | Spironolactone | 123 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 122 | 20 |
| Clonazepam | Clonazepam | 121 | 18 |
| Jardiance | Empagliflozin | 119 | suppressed |
| Bumetanide | Bumetanide | 115 | 19 |
| Azithromycin | Azithromycin | 114 | 62 |
| Meloxicam | Meloxicam | 107 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 107 | 16 |
| Montelukast Sodium | Montelukast Sodium | 106 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 105 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 103 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 17 |
| Bupropion Xl | Bupropion Hcl | 98 | suppressed |
| Levetiracetam | Levetiracetam | 97 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 94 | suppressed |
| Risperidone | Risperidone | 91 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 88 | 50 |
| Olanzapine | Olanzapine | 88 | suppressed |
| Torsemide | Torsemide | 78 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 77 | suppressed |
| Entresto | Sacubitril/Valsartan | 75 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 29 |
| Nystatin | Nystatin | 70 | 33 |
| Clonidine Hcl | Clonidine Hcl | 69 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 68 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 68 | 18 |
| Amoxicillin | Amoxicillin | 67 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 65 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 65 | suppressed |
| Januvia | Sitagliptin Phosphate | 64 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 61 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 61 | suppressed |
| Atenolol | Atenolol | 60 | suppressed |
| Rexulti | Brexpiprazole | 59 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 11 |
| Novolog Flexpen | Insulin Aspart | 57 | 12 |
| Simvastatin | Simvastatin | 57 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 56 | suppressed |
| Pregabalin | Pregabalin | 55 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | suppressed |
| Digoxin | Digoxin | 53 | suppressed |
| Nystop | Nystatin | 53 | 29 |
| Ondansetron Odt | Ondansetron | 53 | 29 |
| Testosterone Cypionate | Testosterone Cypionate | 53 | suppressed |
| Xifaxan | Rifaximin | 51 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 50 | 43 |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 49 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 48 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 18 |
| Insulin Aspart Flexpen | Insulin Aspart | 47 | 12 |
| Xtampza Er | Oxycodone Myristate | 47 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 46 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 20 |
| Colchicine | Colchicine | 43 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 42 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 41 | 22 |
| Latanoprost | Latanoprost | 41 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 25 |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Carbamazepine | Carbamazepine | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 14 |
| Lactulose | Lactulose | 37 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Lacosamide | Lacosamide | 36 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 24 |
| Dapagliflozin | Dapagliflozin Propanediol | 34 | suppressed |
| Fentanyl | Fentanyl | 34 | suppressed |
| Erythromycin | Erythromycin Base | 33 | suppressed |
| Trospium Chloride | Trospium Chloride | 33 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 32 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 11 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Cephalexin | Cephalexin | 30 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Vraylar | Cariprazine Hcl | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Ingrezza | Valbenazine Tosylate | 26 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 17 |
| Gemtesa | Vibegron | 25 | suppressed |
| Invokana | Canagliflozin | 25 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 25 | 14 |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 14 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 12 |
| Methylprednisolone | Methylprednisolone | 21 | 15 |
| Minoxidil | Minoxidil | 21 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Oxycontin | Oxycodone Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Dexamethasone | Dexamethasone | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Mesalamine Dr | Mesalamine | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Nyamyc | Nystatin | 16 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Lorazepam Intensol | Lorazepam | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 13 | 12 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Propylthiouracil | Propylthiouracil | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Simponi | Golimumab | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Brilinta | Ticagrelor | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $746.82 · 33 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, BREZTRI, CAPLYTA, FARXIGA, INGREZZA, KISUNLA, Ozempic, REXULTI, Rybelsus | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error